BioTuesdays

Category - Markets

Markets

Cantor starts Affimed at OW; PT $12

Cantor Fitzgerald initiated coverage of Affimed N.V. (NASDAQ:AFMD) with an “overweight” rating and 12-month price target of $12. The stock closed at $4.23 on Feb. 22. Affimed, which is one of Cantor’s top picks for...

February 23, 2022
Zosano Logo
Markets

BTIG cuts Zosano to neutral from buy; removes PT

BTIG downgraded Zosano Pharma (NASDAQ:ZSAN) to “neutral” from “buy” and removed its price target after the FDA refused to accept the company’s NDA resubmission for M207 to treat acute migraine. Shares of Zosano, which...

February 23, 2022
vTv Therapeutics Logo
Markets

Cantor starts vTv at OW; PT $5

Cantor Fitzgerald launched coverage of vTv Therapeutics (NASDAQ:VTVT) with an “overweight” rating and 12-month price target of $5. The stock closed at 71 cents on Feb. 17. vTv is developing novel orally administered...

February 18, 2022
oramed
Markets

Cantor starts Oramed at OW; PT $20

Cantor Fitzgerald launched coverage of Oramed Pharmaceuticals (NASDAQ:ORMP) with an “overweight” rating and price target of $20. The stock closed at $10.63 on Feb. 17. Oramed is a developing novel drug formulations for...

February 18, 2022
Collegium Pharma
Markets

Cantor ups Collegium Pharma to OW; PT to $26 from $17

Cantor Fitzgerald upgraded Collegium Pharmaceuticals (NASDAQ:COLL) to “overweight” from “neutral” and raised its price target to $26 from $17, citing its agreement to acquire BioDelivery Sciences International.  Shares...

February 14, 2022
Caribou Biosciences
Markets

Brookline starts Caribou Biosciences at buy; PT $19

Brookline Capital Markets initiated coverage of Caribou Biosciences (NASDAQ:CRBU) with a “buy” rating and 12-to-18-month price target of $19. The stock closed at $10.71 on Feb. 11. Caribou is a leading next...

February 14, 2022
Aerovate Therapeutics
Markets

BTIG starts Aerovate Therapeutics at buy; PT $24

BTIG launched coverage of Aerovate Therapeutics (NASDAQ:AVTE) with a “buy” rating and $24 price target. The stock closed at $9.40 on Feb. 10. Aerovate is focused exclusively on developing a dry powder inhaled...

February 11, 2022
SeqLL
Markets

Maxim starts SeqLL at buy; PT $3

Maxim Group initiated coverage of SeqLL (NASDAQ:SQL) with a “buy” rating and price target of $3. The stock closed at $1.60 on Feb. 8. SeqLL is developing true single molecule sequencing (tSMS), a type of short-read...

February 9, 2022